Novo Nordisk Faces Significant Obstacle in Its Preferred Stock Movement
Novo Nordisk, the Danish pharmaceutical company, has seen a positive shift in its future growth prospects, according to analyst Kerry Holford. This optimism stems from the recent presentation of data from a sub-analysis of the Phase-3 REDEFINE 1 study for Cagrilintid, a long-acting amylin analog being tested for weight loss.
The study, which included adults with obesity or overweight and a weight-related co-morbidity, but without diabetes, showed promising results. Cagrilintid was tested both as a monotherapy and in combination with lifestyle modification. The results were impressive, with an average weight loss of 11.8% in the Cagrilintid group, compared to 2.3% in the placebo group.
This positive development has caught the attention of German private bank Berenberg, which has upgraded Novo Nordisk to 'Buy'. Berenberg has also reduced the price target for Eli Lilly from 970 to 830 USD, and now prefers Novo Nordisk over its US competitor in the obesity treatment area.
Eli Lilly's stock, however, has not been faring as well. It has been downgraded from 'Buy' to 'Hold', and its price target has been revised downwards. Consensus estimates for Eli Lilly appear too high, according to Holford.
The positive sentiment towards Novo Nordisk is not limited to Berenberg. DER AKTIONÄR remains optimistic about Novo Nordisk's prospects, and the new CEO of the company has the opportunity to surprise with unexpectedly strong results.
Novo Nordisk's stock is currently strong and showing signs of further mid-week gain. It is approaching its August high of 371.85 Danish Kroner again. A breakthrough above this level would be a significant positive signal for Novo Nordisk's stock.
In light of these developments, Berenberg has reduced the price target for Novo Nordisk from 610 to 425 Danish Kroner. However, new entrants may still have the opportunity to invest in Novo Nordisk, as its growth prospects continue to look promising.
Study leader Timothy Garvey expressed satisfaction with the data, citing the promising potential of Cagrilintid. If approved, Cagrilintid could provide a significant boost to Novo Nordisk's portfolio, further solidifying its position as a leading provider in the treatment of overweight and obesity.
Read also:
- Planned construction of enclosures within Görlitzer Park faces delays
- Foreign financial aid for German citizens residing abroad persists
- United States and Russia prepared to delve deeper into negotiations regarding the Sakhalin 1 oil and gas project
- Heavy-duty zero-emission vehicles may be exempted from tolls for how long, according to the commission's proposal.
